Longeveron Inc.
Qualité des données : 100%
LGVN
Nasdaq
Manufacturing
Chemicals
1,16 €
▲
0,03 €
(2,93%)
Cap. Boursière: 32,50 M
Prix
1,11 €
Cap. Boursière
32,50 M
Fourchette du Jour
—
Fourchette 52 Semaines
—
Volume
—
Ouverture —
Moyenne 50J / 200J
—
Moyenne 50J / 200J
—
Quick Summary
Points Clés
Revenue declined -2,11% annually over 5 years
Negative free cash flow of -18,89 M
Revenue growth is decelerating — 1Y growth trails 5Y average by 47,76%
Croissance
Revenue Growth (5Y)
-2,11%
En dessous de la moyenne du secteur (1,82%)
Revenue (1Y)-49,87%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Qualité
Return on Equity
-200,72%
En dessous de la moyenne du secteur (-53,53%)
ROIC-152,78%
Net Margin-1893,58%
Op. Margin-1942,20%
Sécurité
Debt / Equity
N/A
Current Ratio2,09
Interest CoverageN/A
Valorisation
PE (TTM)
-1,43
Au-dessus de la moyenne du secteur (-1,48)
P/B Ratio3,26
EV/EBITDAN/A
Dividend YieldN/A
Historique des Prix
Tendances Financières
Comparaison Sectorielle
vs médiane du secteur Manufacturing (1366 pairs)
Comparaison Sectorielle
vs médiane du secteur Manufacturing (1366 pairs)| Métrique | Action | Médiane du Secteur |
|---|---|---|
| P/E | -1,4 | -1,5 |
| P/B | 3,3 | 1,6 |
| ROE % | -200,7 | -53,5 |
| Net Margin % | -1893,6 | -41,5 |
| Rev Growth 5Y % | -2,1 | 1,8 |
| D/E | — | 0,3 |
Objectif de Cours des Analystes
3 analystes
Strong Buy
Actuel
1,16 €
Objectif
5,48 €
2,00 €
4,00 €
10,45 €
Prévisions
BPA Prévisionnel
-0,54 €
CA Est.
7,71 M
Estimations de Bénéfices
| Période | BPA Est. | CA Est. | Analystes |
|---|---|---|---|
| FY2027 |
-0,54 €
-0,90 € – -0,34 €
|
7,71 M | 3 |
| FY2026 |
-0,40 €
-0,40 € – -0,40 €
|
838 670,0 | 1 |
| Période | BPA Est. | CA Est. | Analystes |
|---|---|---|---|
| 2026 Q2 |
-0,17 €
-0,20 € – -0,12 €
|
268 670,0 | 3 |
| 2026 Q1 |
-0,17 €
-0,21 € – -0,12 €
|
312 670,0 | 3 |
Surprises de Résultats
Derniers 4 trimestres
| Trimestre | BPA Est. | BPA Réel | Surprise |
|---|---|---|---|
| Q42025 | -0,37 € | -0,22 € | +40,0% |
| Q32025 | -0,26 € | -0,39 € | -52,0% |
| Q22025 | -0,35 € | -0,33 € | +6,4% |
| Q12025 | -0,33 € | -0,34 € | -3,8% |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | -49,87% | Revenue Growth (3Y) | 30,04% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | -2,11% | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 1,20 M | Net Income (TTM) | -22,70 M |
| ROE | -200,72% | ROA | -140,56% |
| Gross Margin | 66,97% | Operating Margin | -1942,20% |
| Net Margin | -1893,58% | Free Cash Flow (TTM) | -18,89 M |
| ROIC | -152,78% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 2,09 |
| Interest Coverage | N/A | Asset Turnover | 0,07 |
| Working Capital | 5,40 M | Tangible Book Value | 7,66 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -1,43 | Forward P/E | N/A |
| P/B Ratio | 3,26 | P/S Ratio | 27,11 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -58,12% | ||
| Market Cap | 32,50 M | Enterprise Value | 23,26 M |
| Per Share | |||
| EPS (Diluted TTM) | -1,29 | Revenue / Share | 0,04 |
| FCF / Share | -0,65 | OCF / Share | -0,64 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | 20,43% | FCF Conversion | 83,20% |
| SBC-Adj. FCF | -21,60 M | Growth Momentum | -47,76 |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1,20 M | 2,39 M | 709 000,0 | 1,22 M | 1,31 M |
| Net Income | -22,70 M | -15,97 M | -21,41 M | -18,84 M | -17,05 M |
| EPS (Diluted) | -1,29 | -2,62 | -1,02 | -0,90 | — |
| Gross Profit | 803 000,0 | 1,88 M | 221 000,0 | 497 000,0 | 590 000,0 |
| Operating Income | -23,29 M | -16,52 M | -21,03 M | -18,04 M | -17,46 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 12,04 M | 8,14 M | 9,07 M | 9,37 M | 7,09 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | 800 000,0 | 700 000,0 | 700 000,0 | 0,7 | 0,7 |
| Interest Expense | — | — | — | 1,40 M | 4 000,0 |
| Income Tax | 0,0 | 0,0 | 0,0 | — | — |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 10,26 M | 25,56 M | 12,08 M | 27,41 M | 42,77 M |
| Total Liabilities | 4,59 M | 3,67 M | 5,34 M | 6,91 M | 5,31 M |
| Shareholders' Equity | 5,68 M | 21,89 M | 6,74 M | 20,50 M | 37,45 M |
| Total Debt | — | — | — | — | 311 000,0 |
| Cash & Equivalents | 4,66 M | 19,23 M | 4,95 M | 10,50 M | 25,66 M |
| Current Assets | 5,45 M | 19,62 M | 5,85 M | 20,28 M | 35,38 M |
| Current Liabilities | 4,09 M | 2,58 M | 3,89 M | 4,87 M | 2,71 M |
{"event":"ticker_viewed","properties":{"ticker":"LGVN","listing_kind":"stock","pathname":"/stocks/lgvn","exchange":"Nasdaq","country":"US"}}